STOCK TITAN

Pulse Biosciences, Inc - PLSE STOCK NEWS

Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.

Pulse Biosciences, Inc. (PLSE) is a pioneering clinical-stage electroceutical company focused on the commercial application of its proprietary Nano-Pulse Stimulation (NPS) technology. Headquartered in Hayward, CA, the company's core mission is to leverage this novel technology to improve and extend patient lives, addressing the distinct needs of patients and physicians alike.

Nano-Pulse Stimulation Technology

NPS is a cutting-edge, non-thermal, drug-free energy-based technology that utilizes ultra-short nanosecond electrical pulses to impact cell membranes and intracellular structures. This method promotes unique cellular behaviors and can induce specific immune responses, opening up a myriad of therapeutic possibilities. Unlike conventional treatments, NPS delivers electrical pulses in billionths of a second, providing targeted effects without damaging surrounding tissues.

Applications and Innovations

Pulse Biosciences is actively exploring the potential of its NPS technology across various medical fields. Key areas of investigation include immuno-oncology, where NPS may be used to treat cancer by modulating the immune system's response, and dermatology, for treatments that require precise, non-invasive interventions. The technology's unique biologic effects position it as a promising solution for conditions lacking optimal treatments.

Recent Achievements and Projects

The company has made significant strides in both preclinical and clinical studies, demonstrating the safety and efficacy of NPS technology. Recent projects have focused on refining device capabilities, enhancing treatment protocols, and expanding the scope of applications. Partnerships with leading medical institutions and ongoing collaborations with researchers underscore Pulse Biosciences' commitment to innovation.

Financial Condition

Pulse Biosciences generates substantial revenue primarily from the sale of its systems in North America. The company continues to invest in research and development to further advance its technology and explore new market opportunities.

For those looking to stay updated on the latest developments, performance, and news related to Pulse Biosciences, Inc., StockTitan provides a comprehensive and timely resource.

Rhea-AI Summary
Pulse Biosciences (PLSE) to host Third Quarter 2023 Financial Results conference call on November 13, 2023. The company reported advancements in cardiac ablation technology, appointment of a renowned cardiothoracic surgeon, and positive results from thyroid clinical feasibility study. Financially, GAAP and non-GAAP costs and expenses decreased compared to the prior year period. Cash and cash equivalents totaled $50.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
-
Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) to Host Conference Call and Report Q3 2023 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
-
Rhea-AI Summary
Pulse Biosciences (PLSE) will report Q3 2023 financial results on November 13, 2023, after market close. The company focuses on using its nsPFA technology for the treatment of atrial fibrillation. A conference call will be held at 1:30pm PT / 4:30pm ET, and a webcast will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
Rhea-AI Summary
Pulse Biosciences announces the appointment of Dr. Niv Ad as Chief Science Officer, Cardiac Surgery. Dr. Ad believes that the company's nsPFA technology has the potential to replace other energy modalities in cardiac ablation and significantly expand the number of patients treated in cardiac surgery. His expertise will contribute to the development of the company's product portfolio for cardiac surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
management
-
Rhea-AI Summary
Pulse Biosciences collaborates with CardioNXT to support first-in-human study on atrial fibrillation treatment using nsPFA technology. Integration of nsPFA catheter with CardioNXT's iMap system offers superior accuracy and stability. First-in-human study to begin in H1 2023. Positive potential for best-in-class clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Summary
Pulse Biosciences' nsPFA technology to be featured at Global EP Summit 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.57%
Tags
none
Rhea-AI Summary
Pulse Biosciences announces positive results from a clinical feasibility study on nsPFA technology for treating benign thyroid tumors or nodules. The study shows complete ablation of cellular tissue without damage to noncellular structures. The findings suggest that nsPFA could be a significant advancement in treatment, with advantages including cellular tissue selectivity, sharp ablation zone margins, absence of thermally induced necrosis, and short treatment times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Summary
Pulse Biosciences to present at Gilmartin Group Emerging Growth Showcase on Sept 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences acquisition
-
Rhea-AI Summary
Pulse Biosciences provides clarification on SEC form filing, no intention to sell shares by Robert Duggan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
Rhea-AI Summary
Pulse Biosciences announced financial results for Q2 2023, reporting positive preclinical results for its nsPFA cardiac clamp and catheter products. The company achieved positive patient tolerance and safety in a first-in-human feasibility study for the ablation of benign thyroid nodules. Pulse Biosciences entered into a $65 million private placement stock purchase agreement with Executive Chairman Robert Duggan, strengthening its balance sheet. The company also reported a decrease in operating expenses compared to the prior year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags

FAQ

What is the current stock price of Pulse Biosciences (PLSE)?

The current stock price of Pulse Biosciences (PLSE) is $17.68 as of November 22, 2024.

What is the market cap of Pulse Biosciences (PLSE)?

The market cap of Pulse Biosciences (PLSE) is approximately 1.0B.

What is Pulse Biosciences, Inc.?

Pulse Biosciences, Inc. is a clinical-stage electroceutical company focused on commercializing its proprietary Nano-Pulse Stimulation technology.

What is Nano-Pulse Stimulation (NPS) technology?

NPS is a non-thermal, drug-free energy-based technology that uses nanosecond electrical pulses to affect cell membranes and intracellular structures.

What are the primary applications of NPS technology?

NPS technology is being investigated for use in immuno-oncology and dermatology, among other medical fields.

Where is Pulse Biosciences, Inc. headquartered?

The company's headquarters are located in Hayward, CA.

How does NPS technology differ from traditional treatments?

NPS delivers ultra-short electrical pulses that target cells without damaging surrounding tissues, unlike conventional treatments.

What recent achievements has Pulse Biosciences made?

The company has demonstrated the safety and efficacy of NPS in preclinical and clinical studies and is refining its technology.

What are the financial sources for Pulse Biosciences?

The company generates substantial revenue from the sale of its systems, primarily in North America.

How does Pulse Biosciences contribute to medical innovation?

Pulse Biosciences collaborates with leading medical institutions and researchers to advance its NPS technology and explore new applications.

What is the mission of Pulse Biosciences?

The mission is to design, produce, and commercialize Nano-Pulse technology to improve and extend patients' lives.

How can I get the latest updates on Pulse Biosciences?

You can stay informed about the latest developments by following updates on platforms like StockTitan.

Pulse Biosciences, Inc

Nasdaq:PLSE

PLSE Rankings

PLSE Stock Data

1.04B
17.26M
71.93%
9.32%
4.12%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
HAYWARD